Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $220,658 | $45,349 | $203,864 | $499,660 |
| - Cash | $139,526 | $167,467 | $92,302 | $173,984 |
| + Debt | $62,075 | $63,571 | $65,191 | $66,213 |
| Enterprise Value | $143,207 | -$58,547 | $176,753 | $391,889 |
| Revenue | $9,936 | $14,880 | $23,488 | $15,093 |
| % Growth | -33.2% | -36.6% | 55.6% | – |
| Gross Profit | $7,684 | $11,913 | $23,488 | $15,093 |
| % Margin | 77.3% | 80.1% | 100% | 100% |
| EBITDA | -$157,195 | -$87,553 | -$79,633 | -$79,211 |
| % Margin | -1,582.1% | -588.4% | -339% | -524.8% |
| Net Income | -$164,574 | -$94,654 | -$86,558 | -$84,038 |
| % Margin | -1,656.3% | -636.1% | -368.5% | -556.8% |
| EPS Diluted | -5.81 | -7.49 | -13.84 | -18.25 |
| % Growth | 22.4% | 45.9% | 24.2% | – |
| Operating Cash Flow | -$109,707 | -$123,065 | -$99,540 | -$57,364 |
| Capital Expenditures | -$272 | -$1,241 | -$1,245 | -$3,336 |
| Free Cash Flow | -$109,979 | -$124,306 | -$100,785 | -$60,700 |